Spinale Muskelatrophie
G-BA action
suspension
2020-12-03
Evidence-checked summary
The G-BA issued a suspension on 2020-12-03. The official page states that it took effect as follows: aufgehoben. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Official case record
No inferred stages
Consultation record
2020-11-09
185 parsed turns
Oral hearing: Onasemnogen-Abeparvovec (Spinale Muskelatrophie)
Official Wortprotokoll · 26 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
2020-11-20
quality measure
The G-BA issued a quality measure on 2020-11-20. The official page states that it took effect as follows: aufgehoben. The page lists ATMP-Qualitätssicherungs-Richtlinie as the normative target.
4 official documents · 3 cited claims
2020-12-03
suspension
The G-BA issued a suspension on 2020-12-03. The official page states that it took effect as follows: aufgehoben. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
2 official documents · 3 cited claims
Official sources